Unilife Corp

Unilife — Shareholder Meeting (December 2010)

48 slides from Unilife's shareholder meeting presentation, Dec 6, 2010

  1. Slide 1: December 1, 2010 Annual General Meeting

    1 December 1, 2010 Annual General Meeting

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward- looking statements are based on management's beliefs and assumptions and on information currently available to our m

  3. Slide 3: Chairman's Welcome Mr Jim Bosnjak

    3 Chairman's Welcome Mr Jim Bosnjak

  4. Slide 4: Introducing the Board of Directors: Jim Bosnjak

    4 Introducing the Board of Directors Jim Bosnjak OAM Non-Executive Chairman Australian business leader Strong ties to Asia and EU Joined Unilife Board in 2003 Elected Non-Executive Chairman in 2006

  5. Slide 5: Introducing the Board of Directors: Alan Shortall

    5 Introducing the Board of Directors Alan Shortall CEO and Executive Director Founded Unilife in 2002 Experienced entrepreneur Led the Company in its global business expansion Built a strong, qualified team Passionate, focused and respected leader of Unilife

  6. Slide 6: Introducing the Board of Directors: William Galle

    6 Introducing the Board of Directors William Galle Non-Executive Director Appointed in 2008 U.S-based consultant with 30+year background in U.S business / investment sector Serves on Compensation, Nominating and Corporate Governance Committees.

  7. Slide 7: Introducing the Board of Directors: John Lund

    7 Introducing the Board of Directors John Lund, CPA Non-Executive Director Appointed in 2009 20 years expertise in SEC reporting, compliance, M&A, and public accounting audit services for public companies Chair of the Audit Committee Member of the Strategic Partnerships, Compensation, and Nominating

  8. Slide 8: Introducing the Board of Directors: Mary-Kate Wold

    8 Introducing the Board of Directors Mary-Kate Wold, JD Non-Executive Director Appointed in 2010 Previously the SVP of Finance and the SVP of Tax and Treasury at Wyeth Partner at Shearman & Sterling Chair of Strategic Partnerships Committee and serves on the Audit Committee.

  9. Slide 9: Introducing the Board of Directors: Marc Firestone

    9 Introducing the Board of Directors Marc Firestone, JD Non-Executive Director Appointed during 2010 Executive Vice President and General Counsel for Kraft Foods Chair of the Unilife Nominating and Corporate Governance Committee Member of the Strategic Partnerships Committee

  10. Slide 10: Senior Management in Attendance

    Senior Management in Attendance Richard Wieland CFO Chris Naftzger General Counsel, Corporate Secretary and Chief Compliance Officer Stephen Allan VP, Marketing Dennis Pyers VP, Controller & CAO Cynthia Lighty VP, Human Resources Deborah Karlak Director, SEC Reporting 10

  11. Slide 11: Our Ambition

    Our Ambition To become a global leader of innovative safety medical devices that set the industry benchmark for injection safety. Together with our pharmaceutical and healthcare partners, we will help optimize drug lifecycles, protect healthcare workers, enhance patient care and prevent disease. 11

  12. Slide 12: Our Products

    Our Products Designed in collaboration with healthcare workers and pharmaceutical industry leaders Developed a full proprietary portfolio with best-in-class features All products share a unique technology platform of passive and fully integrated safety Positioned to address unmet needs of markets be

  13. Slide 13: Our Production Systems

    Our Production Systems Proudly manufactured in the United States Use of fully automated assembly systems Aligned with global manufacturing industry leaders Facilities and processes designed to meet stringent pharmaceutical standards for quality 13

  14. Slide 14: Our People

    Our People World-class team Drawn from across the U.S. and the world Believe in our commercial and humanitarian potential 25 years average industry experience Focused on delivery of key business milestones 14

  15. Slide 15: Our Partners

    Our Partners Are established, respected pharmaceutical and healthcare industry leaders Recognize our ability to custom-design devices that can be 'products of choice' Excited by our potential to facilitate the convergence of drugs and devices: Optimize product lifecycles Deliver powerful brand diffe

  16. Slide 16: Our Thanks

    Our Thanks To shareholders for their confidence in Unilife To staff for their tireless commitment to excellence To our Board for their counsel and guidance To our growing network of partners for their support 16

  17. Slide 17: Agenda

    Agenda 17 Confirmation of Quorum Resolutions Items 1.1-1.7 Election of Directors* Item 2. Appointment of public accounting firm Item 3. Granting of Options to Mary-Kate Wold Item 4. Granting of Options to Marc Firestone 2010 Achievements and Outlook - Alan Shortall Questions Confirmation of Results

  18. Slide 18: Confirmation of Quorum

    Confirmation of Quorum Unilife's quorum requirement is one-third of outstanding shares being represented either in person or by proxy Unilife has received at least 44.92% of the total outstanding shares entitled to vote are represented by person or by proxy. 18

  19. Slide 19: Election of Directors Item 1.

    Election of Directors Item 1. 19 19

  20. Slide 20: Item 2. Ratify appointment of KPMG LLP

    Item 2. 20 To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending year ending June 30, 2011 the fiscal year ending year ending June 30, 2011 the fiscal year ending year ending June 30, 2011 the fiscal year ending year ending June 30, 201

  21. Slide 21: Item 3. Option grant to Mary Katherine Wold

    Item 3. Item 3. 21 For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of options for Mary Katherine Wold to purchase 100,000 shares of common stock on the terms and conditions set forth in the accompanying proxy statement

  22. Slide 22: Item 4. Option grant to Marc S. Firestone

    Item 4. 22 For the purposes of ASX Listing Rule 10.14 and for all other purposes, to approve the grant of options for Marc S. Firestone to purchase 100,000 shares of common stock on the terms and conditions set forth in the accompanying proxy statement forth in the accompanying proxy statement forth

  23. Slide 23: 2010 Achievements and Business Outlook

    23 2010 Achievements and Business Outlook CEO Alan Shortall

  24. Slide 24: 2010 - A Year of Transformation

    2010 - A Year of Transformation Transition into a dual-listed U.S. based company Build industrial capabilities to meet projected market demand Complete preparations for commercial production and supply Continue to enhance strength of our world-class team Expand relationships with pharmaceutical indu

  25. Slide 25: Became a U.S. Based Dual Listed Business

    Became a U.S based dual listed business Completed redomiciliation to the U.S. Form 10 declared effective Listing on NASDAQ global market exchange Inclusion on several indexes including Russell 2000 Many U.S. institutions now part of share registry 25

  26. Slide 26: Built a World-Class Team

    Built a World-Class Team Now 175 staff employed globally Management team has average 25 years of industry expertise Recently added experienced CFO, General Counsel and Controller Further strengthening of Board Mary Kate Wold Marc Firestone 26

  27. Slide 27: Built a State-of-the-Art Facility

    27 Built a State-of-the-Art Facility 165,000sqf state-of-the-art facility designed to meet stringent pharmaceutical standards Commenced groundwork in December 2009 Ready for operations within two weeks Photo taken Nov 23, 2010

  28. Slide 28: $31m project backed by strong government programs

    28 $31m project backed by strong government programs Designed to comply with stringent pharmaceutical standards Capacity to produce up to 400m syringes per year - potential to expand to one billion units Built a State-of-the-Art Facility Photo taken Nov 23, 2010

  29. Slide 29: Cleanrooms

    Cleanrooms 29 11 clean room suites totaling 21,600 sq foot 2 ISO Class 7 suites (USP 5.5) 9 ISO Class 8 suites (USP 6.5) Built a State-of-the-Art Facility Photo taken Nov 23, 2010

  30. Slide 30: Offices

    Photo taken Nov 23, 2010 30 Office space for up to 200 staff Built a State-of-the-Art Facility Offices

  31. Slide 31: Warehouse

    31 Fully segregated 20,000 square foot warehouse Built a State-of-the-Art Facility Photo taken Nov 23, 2010

  32. Slide 32: Built an Advanced Quality System

    Built an Advanced Quality System Electronic Master Control system Developed procedures to comply to ISO and pharma industry standards for drug containers Audited by TUV, sanofi-aventis and other pharmaceutical groups U.S. made Unitract 1mL syringes FDA clearance CE Mark (EU), Australian and Canadian

  33. Slide 33: Unifill Ready-to-Fill Syringe

    Unifill Ready-to-Fill Syringe 34 Primary drug container Only prefilled syringe with safety integrated inside the glass barrel USP compliant materials Integration into fill-finish systems Optimal protection from harm Compact handling, intuitive use Ideal for lifecycle management Strong patent positio

  34. Slide 34: Unifill Washing, Siliconization and WFI Systems

    Unifill Ready-to-Fill Syringe 36 Washing, Siliconization and WFI Systems Groninger washing and siliconization system Global industry leader for vial and syringe processing Proven off-the-shelf system (150mm units / year) Factory acceptance test complete Meco Water for Injection (WFI) Now installed i

  35. Slide 35: Independent evaluation with experienced U.S. nurses

    Independent evaluation with experienced U.S nurses Against 2 leading prefilleds (clip-on safety) Unifill strongly preferred for functionality, safety, ease-of-use, performance and appearance Half could find no fault with Unifill 50% liked its relatively compact size Most favoring Device A had larger

  36. Slide 36: Completion of Industrialization Program

    39 Unifill Ready-to-Fill Syringe 39 Completion of Industrialization Program Approaching program completion Successfully met nine straight quarterly milestones ($22.5m) One milestone remaining Install qualified Mikron line: Q1 2011 Start commercial sales: Q2 2011 Secure collaboration and / or Supply

  37. Slide 37: Pharmaceutical Relationships: sanofi-aventis

    Pharmaceutical Relationships Contributed approximately $40m for exclusive right to negotiate purchase of Unifill syringe until June 2014 Both parties agreed to exclusivity list in March 2010 Thrombotics, vaccines & 4 other new pre-filled areas Ten year exclusivity extension per drug class if commerc

  38. Slide 38: Pharmaceutical Relationships

    Pharmaceutical Relationships 41 Initial Discussions Interest in Collaboration Request Samples for Validation Collaboration Agreement Supply Agreements Sanofi-aventis Pharma 2 Pharma 3 Pharma 4 Pharma 5 Pharma 6 Pharma 7 Pharma 8 Pharma 9 Pharma 10 Pharma 11 Pharma 12 Pharma 13 Pharma 14 Pharma 15 Ph

  39. Slide 39: Potential Unifill Drug Candidates

    42 42 Potential Unifill Drug Candidates Indicative table of marketed and pipeline drugs (83) that are potential Unifill targets Sanofi- aventis Additional pharmaceutical companies (P) with drugs outside of classes already retained

  40. Slide 40: Optimizing Lifecycle Management

    43 Optimizing Lifecycle Management Unique - not a commodity Powerful brand differentiation in competitive markets Potential to extend lifecycle of drugs nearing expiration Potential to raise unit prices Potential for unique claims with combination product Potential to obstruct entry of biosimilars o

  41. Slide 41: Unitract 1mL Syringe

    Unitract 1ml Syringe 44 World's only 1mL syringes with passive, controllable retraction U.S. made Insulin and TB syringes certified in key markets Appointed IMCO as initial preferred U.S. launch partner Business development partners India, Taiwan, Japan and China Regulatory approvals in 2011 Discuss

  42. Slide 42: New Product Development

    Ready-to-Fill syringes (glass barrel) Project Taipan Clinical syringes (for use with vials) Project Liger New Product Development Unifill syringe Unifill Select Unitract 1mL Unitract Clinical Confidential Projects 45

  43. Slide 43: Milestones

    46 2010 H2 2011 (H1) 2011 (H2) > 2012 US Unitract Sales Finish York facility building Cleanroom qualification Install UnifillTM 60m line Open York facility File Drug Master File Collaboration agreements Unifill production Unifill Sales Supply Agreements Unifill 150m line Pipeline products Milestones

  44. Slide 44: Summary

    47 Summary Markets driven by legislation to mandatory use of safety syringes Developed full portfolio of syringes with best-in-class safety features World's only pre-filled syringe with safety integrated inside barrel $40 million validating partnership with sanofi-aventis Accelerating talks with man

  45. Slide 45: Questions

    uniuire®? Questions

  46. Slide 46: Summary of Final Voting

    Summary of Final Voting Successful passage of all Resolutions Items 1.1-1.7 Election of Directors* Item 2. Appointment of public accounting firm Item 3. Granting of Options to Mary-Kate Wold Item 4. Granting of Options to Marc Firestone 49

  47. Slide 47: Australian Investor Meetings

    Australian Investor Meetings For Australian-based shareholders unable to attend Unilife's 2010 Annual General Meeting, Unilife CEO Alan Shortall will host the following investor meetings Sydney, NSW Radisson Plaza Hotel, 27 O'Connell Street, Sydney Friday, December 17, 2010 from 10.30am Melbourne, V

  48. Slide 48: Meeting Closes

    uniuire® ‘medical solutions Meeting Closes

Unilife — Shareholder Meeting (December 2010) on 6ix